These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25141889)

  • 1. Cell replacement therapies: is it time to reprogram?
    Mikkers HM; Freund C; Mummery CL; Hoeben RC
    Hum Gene Ther; 2014 Oct; 25(10):866-74. PubMed ID: 25141889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Converting cell fates: generating hematopoietic stem cells de novo via transcription factor reprogramming.
    Daniel MG; Lemischka IR; Moore K
    Ann N Y Acad Sci; 2016 Apr; 1370(1):24-35. PubMed ID: 26748878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell-based therapies in Parkinson's disease: future hope or current treatment option?
    Loewenbrück K; Storch A
    J Neurol; 2011 May; 258(Suppl 2):S346-53. PubMed ID: 21437664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reprogramming of somatic cells. Problems and solutions].
    Schneider TA; Fishman VS; Liskovykh MA; Ponamartsev SV; Serov OL; Tomilin AN; Alenina N
    Tsitologiia; 2014; 56(12):869-80. PubMed ID: 25929128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human parthenogenetic embryonic stem cells: one potential resource for cell therapy.
    Hao J; Zhu W; Sheng C; Yu Y; Zhou Q
    Sci China C Life Sci; 2009 Jul; 52(7):599-602. PubMed ID: 19641863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors.
    Park TS; Huo JS; Peters A; Talbot CC; Verma K; Zimmerlin L; Kaplan IM; Zambidis ET
    PLoS One; 2012; 7(8):e42838. PubMed ID: 22905176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cell therapy for Parkinson's disease with induced pluripotent stem cells].
    Morizane A
    Rinsho Shinkeigaku; 2019 Mar; 59(3):119-124. PubMed ID: 30814448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regenerative therapy for post-stroke patients].
    Yamashita T; Abe K
    Nihon Rinsho; 2016 Apr; 74(4):661-5. PubMed ID: 27333756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in stem cell therapy for major human neurological disorders.
    Martínez-Morales PL; Revilla A; Ocaña I; González C; Sainz P; McGuire D; Liste I
    Stem Cell Rev Rep; 2013 Oct; 9(5):685-99. PubMed ID: 23681704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
    Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
    CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteogenic stem-cell characterization and development: potentials for cytotherapy.
    Triffitt JT; Oreffo RO; Virdi AS; Xia Z
    Cytotherapy; 2001; 3(5):413-6. PubMed ID: 11953025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status and perspective on regenerative medicine for spinal cord injury using iPS cell].
    Nakamura M; Toyama Y; Okano H
    Rinsho Shinkeigaku; 2013; 53(11):1013-5. PubMed ID: 24291863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.
    Vanikar AV; Trivedi HL; Thakkar UG
    Cytotherapy; 2016 Sep; 18(9):1077-86. PubMed ID: 27424148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage.
    Sridhar A; Ohlemacher SK; Langer KB; Meyer JS
    Stem Cells Transl Med; 2016 Apr; 5(4):417-26. PubMed ID: 26933039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier.
    Papapetrou EP
    Adv Exp Med Biol; 2017; 1013():219-240. PubMed ID: 29127683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotency: history, mechanisms, and applications.
    Stadtfeld M; Hochedlinger K
    Genes Dev; 2010 Oct; 24(20):2239-63. PubMed ID: 20952534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo generation of HSCs from somatic and pluripotent stem cell sources.
    Vo LT; Daley GQ
    Blood; 2015 Apr; 125(17):2641-8. PubMed ID: 25762177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of human adipose-derived stem cells in neurological disorders.
    Chang KA; Lee JH; Suh YH
    J Pharmacol Sci; 2014; 126(4):293-301. PubMed ID: 25409785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-specific pluripotent stem cells: promises and challenges.
    Müller R; Lengerke C
    Nat Rev Endocrinol; 2009 Apr; 5(4):195-203. PubMed ID: 19352317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.